David Sallman, MD
Assistant Member, Malignant Hematology Department
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator
MDS Factsheet for GPs General Practicioners
Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.
This is an external link to the home of the British Society for Haematology (BSH).